APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-β

Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?

(2023) Jennifer J. Manly et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Donanemab in Early Symptomatic Alzheimer Disease

(2023) John R. Sims et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Associations of Sex, Race, and Apolipoprotein E Alleles With Multiple Domains of Cognition Among Older Adults

(2023) Skylar Walters et al.   JAMA Neurology

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

(2022) Rik Ossenkoppele et al.   NATURE MEDICINE

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease

(2020) Tosha Williams et al.   Molecular Neurodegeneration

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects

(2020) Ruben Smith et al.   BRAIN

A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward

(2019) Michaël E. Belloy et al.   NEURON

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

(2019) Rik van der Kant et al.   NATURE REVIEWS NEUROSCIENCE

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

(2018) Niklas Mattsson et al.   Alzheimers & Dementia

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia